

# Status of Development Pipeline (As of July 26, 2021)

## Main Status of Development Pipelines (Oncology)

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
OPDIVO Intravenous Infusion (Nivolumab)	Anti-PD-1 antibody	Esophageal cancer (Adjuvant therapy)	→				JP	In-house (Co-development with Bristol-Myers Squibb)
			→				KR · TW	
		Urothelial carcinoma (Adjuvant therapy)	→				JP	
		Cancer of unknown primary	→				JP	
		Hodgkin's lymphoma (Pediatric)	→				JP	
		Ovarian cancer	→				JP	
		Bladder cancer	→				JP · KR · TW	
		Prostate cancer	→				JP · KR · TW	
		Hepatocellular carcinoma	→				JP · KR	
		Pancreatic cancer	→				JP · KR · TW	
		Biliary tract cancer	→				JP · KR · TW	
		Virus positive / negative solid carcinoma	→				JP · KR · TW	
YERVOY Injection* (Ipilimumab)	Anti-CTLA-4 antibody	Gastric cancer	→				JP · KR · TW	Co-development with Bristol-Myers Squibb
		Esophageal cancer	→				JP · KR · TW	
		Urothelial cancer	→				JP · KR · TW	
		Hepatocellular carcinoma	→				JP · KR · TW	
		Virus positive / negative solid carcinoma	→				JP · KR · TW	
ONO-7701* (Linrodostat)	IDO1 inhibitor	Bladder cancer	→				JP · KR · TW	Co-development with Bristol-Myers Squibb
BRAFTOVI Capsules (Encorafenib)	BRAF inhibitor	Thyroid cancer	→				JP	Pfizer
		Colorectal cancer	→				KR	
		Melanoma	→				KR	
MEKTOVI Tablets (Binimetinib)	MEK inhibitor	Thyroid cancer	→				JP	Pfizer
		Colorectal cancer	→				KR	
		Melanoma	→				KR	
ONO-4686*	Anti-TIGIT antibody	Solid tumor	→				JP	Co-development with Bristol-Myers Squibb
ONO-4482* (Relatlimab)	Anti-LAG-3 antibody	Melanoma	→				JP	Co-development with Bristol-Myers Squibb
ONO-7807*	Anti-TIM-3 antibody	Solid tumor	→				JP	Co-development with Bristol-Myers Squibb

\*In combination with OPDIVO.

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
ONO-7912 (Devimistat)	Cancer metabolism inhibitor	Pancreatic cancer	→				JP	Rafael
			→	→			KR	
		Acute myeloid leukemia	→	→			KR	
ONO-7475	Axl / Mer inhibitor	Solid tumor*	→				JP	In-house
		Non-small cell lung cancer	→				JP	
		Acute leukemia	→	→			US	
ONO-4059 (Tirabrutinib)	Bruton's tyrosine kinase (BTK) inhibitor	Primary central nervous system lymphoma	→	→			US	In-house
ONO-4578*	PG receptor (EP4) antagonist	Colorectal cancer	→				JP	In-house
		Pancreatic cancer	→				JP	
		Non-small cell lung cancer	→				JP	
		Solid tumor, Gastric cancer	→				JP	
ONO-7911* (Bempegaldesleukin)	PEGylated IL-2	Solid tumor	→				JP	Co-development with Bristol-Myers Squibb
ONO-7913 (Magrolimab)	Anti-CD47 antibody	Pancreatic cancer*	→				JP	Gilead Sciences
		Colorectal cancer*	→				JP	
		Solid tumor	→				JP	
		Myelodysplastic syndrome	→				JP	

★ In combination with OPDIVO.

## Main Status of Development Pipelines (Other than Oncology)

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
ORENCIA SC (Abatacept)	T-cell activation inhibitor	Polymyositis / Dermatomyositis	→	→			JP	Co-development with Bristol-Myers Squibb
ONOACT for Intravenous Infusion (Landiolol Hydrochloride)	Short-active selective $\beta_1$ blocker	Tachyarrhythmia in low cardiac function (Pediatric)	→	→			JP	In-house
VELEXBRU Tablets (Tirabrutinib)	Bruton's tyrosine kinase (BTK) inhibitor	Pemphigus	→	→			JP	In-house
		Generalized scleroderma	→				JP	
Joyclu Intra-articular Injection	Hyaluronic acid-NSAID	Enthesopathy	→	→			JP	Seikagaku
ONO-2910	Schwann cell differentiation promoter	Diabetic polyneuropathy	→	→			JP	In-house
ONO-2808	S1P5 receptor agonist	Neurodegenerative disease	→				JP · EU	In-house
ONO-4685	PD-1×CD3 bispecific antibody	Autoimmune disease	→				JP	In-house
ONO-2909	PG receptor (DP1) antagonist	Narcolepsy	→				JP	In-house
ONO-7684	FXIa inhibitor	Thrombosis	→				EU	In-house